Your browser doesn't support javascript.
loading
Long-term survival after intraperitoneal chemotherapy with paclitaxel-cisplatin for recurrent primary peritoneal cancer resistant to multiple lines of intravenous chemotherapy
Obstetrics & Gynecology Science ; : 285-289, 2019.
Artigo em Inglês | WPRIM | ID: wpr-760645
ABSTRACT
The long-term survival of heavily pretreated patients with primary peritoneal cancer (PPC) is uncommon. Here, we report on a patient with PPC refractory to multiple lines of intravenous chemotherapy, namely, a combined regimen of paclitaxel and carboplatin, and single regimens of topotecan, docetaxel, cisplatin, and gemcitabine. However, after intraperitoneal (IP) chemotherapy with paclitaxel-cisplatin, the patient's condition improved, and she has been progression-free for more than 4 years. Interestingly, before the IP chemotherapy, the recurrences were limited to the peritoneal cavity. These results suggest that IP recurrence might be a predictor of a good response to IP chemotherapy.
Assuntos

Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Assunto principal: Neoplasias Ovarianas / Cavidade Peritoneal / Neoplasias Peritoneais / Recidiva / Carboplatina / Cisplatino / Paclitaxel / Topotecan / Tratamento Farmacológico / Infusões Parenterais Limite: Humanos Idioma: Inglês Revista: Obstetrics & Gynecology Science Ano de publicação: 2019 Tipo de documento: Artigo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Assunto principal: Neoplasias Ovarianas / Cavidade Peritoneal / Neoplasias Peritoneais / Recidiva / Carboplatina / Cisplatino / Paclitaxel / Topotecan / Tratamento Farmacológico / Infusões Parenterais Limite: Humanos Idioma: Inglês Revista: Obstetrics & Gynecology Science Ano de publicação: 2019 Tipo de documento: Artigo